de Oliveira Tássia R, Erbereli Camila R, Manzine Patricia R, Magalhães Thamires N C, Balthazar Marcio L F, Cominetti Márcia R, Faria Ronaldo C
Department of Chemistry, Federal University of São Carlos, São Carlos, São Paulo 13565-905, Brazil.
Department of Gerontology, Federal University of São Carlos, São Carlos, São Paulo 13565-905, Brazil.
ACS Sens. 2020 Apr 24;5(4):1010-1019. doi: 10.1021/acssensors.9b02463. Epub 2020 Apr 2.
Alzheimer's disease (AD) is a neurodegenerative condition that affects a large number of elderly people worldwide and has a high social and economic impact. The diagnosis of AD in early stage can significantly improve the evolution and prognosis of the disease. We report the use of A Disintegrin And Metalloprotease 10 (ADAM10) as a blood biomarker for the early diagnosis of AD. A simple, low-cost, sensitive, and disposable microfluidic platform (DμP) was developed for ADAM10 detection in plasma and cerebrospinal fluid based on electrochemical immunosensors. The assay was designed to accurately detect ADAM10 in serum, with a limit of detection of 0.35 fg/mL. ADAM10 was detected in subjects divided into cognitively healthy subjects, subjects with mild cognitive impairment, and AD patients in different disease stages. An increase in protein levels was found throughout the disease, and good DμP accuracy in differentiating individuals was observed. The DμP provided significantly better sensitivity than the well-established enzyme-linked immunosorbent assay test. ADAM10 and its detection using the DμP were proven to be an alternative tool for the early diagnosis and monitoring of AD, bringing new exciting possibilities to improve the quality of life of AD patients.
阿尔茨海默病（AD）是一种神经退行性疾病，影响着全球大量老年人，具有很高的社会和经济影响。早期诊断AD可显著改善疾病的进展和预后。我们报告了使用解整合素和金属蛋白酶10（ADAM10）作为AD早期诊断的血液生物标志物。基于电化学免疫传感器，开发了一种简单、低成本、灵敏且一次性使用的微流控平台（DμP），用于检测血浆和脑脊液中的ADAM10。该检测方法旨在准确检测血清中的ADAM10，检测限为0.35 fg/mL。在分为认知健康受试者、轻度认知障碍受试者和不同疾病阶段的AD患者的受试者中检测到了ADAM10。在整个疾病过程中发现蛋白质水平升高，并且观察到DμP在区分个体方面具有良好的准确性。DμP提供的灵敏度明显高于成熟的酶联免疫吸附测定试验。ADAM10及其使用DμP进行的检测被证明是AD早期诊断和监测的一种替代工具，为改善AD患者的生活质量带来了新的令人兴奋的可能性。
